Keith C Bible

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8637515/publications.pdf

Version: 2024-02-01

55 papers	14,004 citations	186265 28 h-index	214800 47 g-index
55 all docs	55 docs citations	55 times ranked	10834 citing authors

#	Article	IF	Citations
1	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	2.0	41
2	Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. Journal of the Endocrine Society, 2022, 6, bvac044.	0.2	5
3	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma. , 2021, , 246-254.e3.		0
4	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Thyroid, 2021, 31, 332-333.	4.5	8
5	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2021, 31, 337-386.	4.5	297
6	Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations. Journal of Clinical Oncology, 2021, 39, 1856-1864.	1.6	100
7	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 2021, 39, 2359-2366.	1.6	64
8	Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. AACE Clinical Case Reports, 2021, 7, 334-335.	1.1	2
9	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
10	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. Journal of the Endocrine Society, 2020, 4, bvaa069.	0.2	14
11	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2346-e2357.	3.6	11
12	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid, 2020, 30, 1254-1262.	4.5	19
13	Bone metastases in thyroid cancer. Journal of Bone Oncology, 2020, 21, 100282.	2.4	59
14	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid, 2019, 29, 1615-1622.	4.5	51
15	Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2019, 48, 269-284.	3.2	58
16	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid, 2019, 29, 7-26.	4.5	122
17	Anaplastic Thyroid Carcinoma. , 2019, , 693-700.		0
18	External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. Advances in Radiation Oncology, 2018, 3, 25-29.	1.2	47

#	Article	IF	Citations
19	Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. Endocrine, 2018, 59, 228-229.	2.3	3
20	Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. Annals of Surgical Oncology, 2017, 24, 1546-1550.	1.5	38
21	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1943-1950.	3.6	86
22	Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid, 2017, 27, 923-927.	4.5	31
23	â€œPseudo-progressionâ€•in advanced thyroid cancer in response to kinase inhibitor therapy. Endocrine, 2017, 57, 187-188.	2.3	3
24	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4506-4514.	3.6	86
25	Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine, 2017, 57, 220-225.	2.3	40
26	Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer. Endocrine, 2017, 57, 364-365.	2.3	0
27	Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes and Endocrinology,the, 2017, 5, 469-481.	11.4	58
28	Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncology, The, 2016, 17, 1181-1183.	10.7	5
29	Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. International Journal of Endocrine Oncology, 2016, 3, 285-289.	0.4	7
30	Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. Journal of Oncology Practice, 2016, 12, 521-522.	2.5	0
31	New drugs for medullary thyroid cancer: new promises?. Endocrine-Related Cancer, 2016, 23, R287-R297.	3.1	20
32	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nature Reviews Clinical Oncology, 2016, 13, 403-416.	27.6	80
33	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26, 1-133.	4.5	10,674
34	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4387-4395.	3.6	12
35	Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. International Journal of Endocrine Oncology, 2014, 1, 145-151.	0.4	7
36	A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1687-1693.	3.6	117

#	Article	IF	Citations
37	Development and Characterization of a Differentiated Thyroid Cancer Cell Line Resistant to VEGFR-Targeted Kinase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E936-E943.	3.6	10
38	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes and Endocrinology,the, 2014, 2, 830-842.	11.4	106
39	Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer. Science Translational Medicine, 2013, 5, 166ra3.	12.4	58
40	Development of a Multidisciplinary, Multicampus Subspecialty Practice in Endocrine Cancers. Journal of Oncology Practice, 2012, 8, e1s-e5s.	2.5	11
41	Individualization of Therapies for Patients with Advanced Differentiated Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3092-3093.	3.6	3
42	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 2012, 22, 1104-1139.	4.5	717
43	A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261. Gynecologic Oncology, 2012, 127, 55-62.	1.4	52
44	A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3179-3184.	3.6	148
45	Treating advanced radioresistant differentiated thyroid cancer. Lancet Oncology, The, 2012, 13, 854-855.	10.7	7
46	Systemic Therapeutic Approaches to Advanced Thyroid Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 389-392.	3.8	2
47	Toward improved outcomes in patients with anaplastic thyroid cancer. Oncology, 2012, 26, 398, 401, 406.	0.5	3
48	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. American Journal of Managed Care, 2012, 18, e162-7.	1.1	0
49	Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opinion on Investigational Drugs, 2011, 20, 1357-1375.	4.1	39
50	Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy. Thyroid, 2011, 21, 25-30.	4.5	139
51	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncology, The, 2010, 11, 962-972.	10.7	390
52	Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Molecular Cancer Therapeutics, 2006, 5, 138-148.	4.1	59
53	Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points. Clinical Cancer Research, 2005, 11, 5935-5941.	7.0	65
54	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. Blood, 2004, 104, 3461-3461.	1.4	0

#	Article	IF	Citations
55	Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer. Endocrine, 0, , .	2.3	0